奥沙利铂联合希罗达治疗晚期或复发性结直肠癌的临床观察

目的:观察奥沙利铂联合希罗达(卡培他滨)治疗晚期或复发性结直肠癌的临床疗效及不良反应。方法:32例晚期或复发性结直肠癌患者均给予奥沙利铂130mg/m2静滴(d1),希罗达1000mg/m2,每日两次餐后口服(d1～14),连续服用14d后停药7d。治疗周期为21d,至少治疗2个周期。结果:32例患者中CR0例,PR13例,SD10例,PD9例,总有效率40.6%,中位生存期为15.2个月,中位无进展生存期7.2个月,1年生存率为65.6%。主要毒副反应为周围神经异常、胃肠道毒性、手足综合征、口腔炎症、皮肤色素沉着。结论:奥沙利铂联合希罗达治疗晚期或复发性结直肠癌疗效确切,不良反应小,耐受性好。

The effect of combined oxaliplatin and capecitabine for the treatment of advanced and recurrent colorectal cancer

Objective To observe the efficacy and side effects of the combination of oxaliplatin and capecitabine for patients with advanced and recurrent colorectal cancer. Method The 32 patients with advanced and recurrent colorectal cancer treated with oxaliplatin 130mg/m^2 on the first day and capecitabine given at a dose of 1 000mg/m^2,twice daily on 1-14 days. At last 2 cycles every cycle for 21 days were administered. Results The over all response rate was 40.6% with 0 CR., 13 PR, 10 SD and 9 PD. The median survival time was 15.2 months , the median ailment development time was 7.2 months and the 1 year survival rate was 65.6%. The adverse effects were peripheral neuritis, muse/vomiting/diarrhea, hand-foot syndromed, hyperpigmentation. Conclusion The combination of oxaliplatin and capecitabine is an efficacious and better tolerated treatment for patients with advanced and recurrent colorectal cancer.